Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
China Resources Pharmaceutical Group Ltd. has announced the successful issuance of the first tranche of its Medium Term Notes 2025, amounting to RMB3 billion with a 3-year term and a coupon rate of 2.19% per annum. The proceeds from this issuance will be used to repay interest-bearing debt, potentially strengthening the company’s financial position and operational flexibility.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is involved in a wide range of pharmaceutical services and has a significant market presence in China.
YTD Price Performance: -16.89%
Average Trading Volume: 14,735,023
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.96B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.